Joensuu, H., Sundby Hall, K., Hartmann, J. T., Pinkston, D. A., Schütte, J., & Hohenberger, P. (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. The journal of the American Medical Association, 307(12), . https://doi.org/10.1001/jama.2012.347
Chicago-Zitierstil (17. Ausg.)Joensuu, Heikki, Kirsten Sundby Hall, Jörg Thomas Hartmann, Daniel A. Pinkston, Jochen Schütte, und Peter Hohenberger. "One Vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial." The Journal of the American Medical Association 307, no. 12 (2012). https://doi.org/10.1001/jama.2012.347.
MLA-Zitierstil (9. Ausg.)Joensuu, Heikki, et al. "One Vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial." The Journal of the American Medical Association, vol. 307, no. 12, 2012, https://doi.org/10.1001/jama.2012.347.